Table 2.
Clinical outcome summary scores from clinician interview for patients with psychosis
| Program (n = 53) | Control (n = 21) | ANCOVA | Full cohort (n = 74) | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Mean | SD | Mean | (SD) | Effect size F, partial eta2 |
P-value* | Mean | (SD) | Effect size Z, r |
P-value** | |
| PANSS positive and negative | < 0.01, < 0.01 | 0.96 | 6.87, 0.80 | < 0.0001 | ||||||
| Baseline | 25.5 | 12.1 | 24.9 | 11.9 | 25.3 | − 12 | ||||
| end point | 7.9 | 7.4 | 10.3 | 12.2 | 8.6 | − 9 | ||||
| Δ score | − 17.6 | 12.5 | − 14.6 | 14.1 | − 16.8 | − 12.9 | ||||
| PANSS positive | 1.22, 0.02 | 0.22 | 6.87, 0.80 | < 0.0001 | ||||||
| Baseline | 11.6 | 6.8 | 13.1 | 5.7 | 12 | 6.5 | ||||
| end point | 2.7 | 3.3 | 3.7 | 4.6 | 3 | 4.6 | ||||
| Δ score | − 8.9 | 7.7 | − 9.3 | 7.5 | − 9 | 7.5 | ||||
| PANSS negative | 2.16, 0.03 | 0.69 | 6.42, 0.75 | < 0.0001 | ||||||
| Baseline | 13.9 | 7.3 | 11.8 | 7.4 | 13.3 | 7.4 | ||||
| end point | 5.2 | 5.3 | 6.6 | 7.7 | 5.6 | 6.1 | ||||
| Δ score | − 8.7 | 7 | − 5.2 | 8 | − 7.7 | 7.4 | ||||
| HAM-D | 0.02, < 0.01 | 0.27 | 6.02, 0.70 | < 0.0001 | ||||||
| Baseline | 15.6 | 7.2 | 16.3 | 7.8 | 15.8 | 7.3 | ||||
| end point | 7.7 | 4.5 | 8.0 | 6.7 | 7.8 | 6.7 | ||||
| Δ score | − 7.8 | 8.0 | − 8.4 | 11.3 | − 8.0 | 9.0 | ||||
HAM-D Hamilton Depression Scale, PANSS positive and negative syndrome scale
* P-value taken from ANCOVA (analysis of covariance) for each scale comparing program vs. control scores at end point, adjusted for baseline score
** P-value from Wilcoxon Signed-Rank Test comparing baseline to end point scores (full cohort)